Moderna says Covid-19 vaccine immunity to stay at least a year

Published Tue, Jan 12, 2021 · 07:09 AM

[BENGALURU] Immunity from Moderna Inc's Covid-19 vaccine should last at least a year, the company said on Monday at the JPMorgan Healthcare conference.

The drugmaker said it was confident that the messenger RNA (mRNA) technology it used was well suited to deploy a vaccine based on the new variant of the coronavirus which has emerged in a handful of countries.

The company's vaccine, mRNA-1273, uses synthetic mRNA to mimic the surface of the coronavirus and teach the immune system to recognise and neutralise it.

Moderna said in December it would run tests to confirm the vaccine's activity against any strain.

The company said on Monday it expects to deliver between 600 million doses and 1 billion does of its vaccine in 2021 and forecast vaccine-related sales of US$11.7 billion for the year, based on advance purchase agreements signed with governments.

"The team feels very comfortable with the track record we have now ... that we are on track to deliver at least 600 million doses," chief executive officer Stéphane Bancel said.

GET BT IN YOUR INBOX DAILY

Start and end each day with the latest news stories and analyses delivered straight to your inbox.

VIEW ALL

REUTERS

KEYWORDS IN THIS ARTICLE

BT is now on Telegram!

For daily updates on weekdays and specially selected content for the weekend. Subscribe to  t.me/BizTimes

International

SUPPORT SOUTH-EAST ASIA'S LEADING FINANCIAL DAILY

Get the latest coverage and full access to all BT premium content.

SUBSCRIBE NOW

Browse corporate subscription here